We recently reported the biological activity and some of the biochemical characteristics of a factor produced by a human T cell hybrid clone able to block hematopoietic progenitor cell proliferation. This 85-kD protein factor, which we have termed colony-inhibiting lymphokine (CIL), has growth regulatory activity on bone marrow precursors bearing Ia (class II) antigens of either granulocytic-monocytic (CFU-GM) or erythroid lineage (BFU-E and CFU-E). Experiments aimed to investigate the specificity of the inhibitory effect on hematopoietic progenitor cell growth suggested that the expression of HLA-DR surface antigens was required on the target cells. We describe in this communication how DR' cell lines ceased dividing after a few days of culture in the presence of CIL, whereas DR-cell lines were completely unaffected. The increased DR expression on the ML3 cell surface, mediated by the activity of the gamma interferon (IFNy), increases the sensitivity to the growth inhibition factor of the ML3 cell line. To verify the hypothesis that the DR antigens might serve as receptors for the factor, enabling it also to interfere in the immune response, we tested CIL in a mixed lymphocyte reaction (MLR), one of the best known in vitro Ia antigen-dependent T cell-mediated immune responses. CIL is able to block major histocompatibility comnplex-allogeneic MLR both in human and mouse systems. The data indicate that CIL recognizes a nonpolymorphic structure (presumably on all Ia molecules) presented by stimulator cells of either species, and thereby interferes with specific interactions between stimulator and responder cells. Blocking of the alloantigen stimulation stage is also indicated, since CIL is effective only if added to the culture medium during the first 48 h of the MLR. Finally, mouse monoclonal anti-DR antibodies are able to sharply reduce CIL activity on sensitive DR' cell lines. CIL may act physiologically as a multifunctional mediator in a complex network that links regulation of bone marrow differentiation and the generation of immune responses.
Introduction
Hematopoiesis is a dynamic process involving the balanced action of both enhancing and inhibiting regulator cells that act either directly or through soluble mediators. Among the best known enhancing factors are the granulocytic-monocytic colony-stimulating factor (CSF)' (1) (2) (3) , and the burst-promoting activity (BPA) (4) factor, which, in association with erythropoietin, is able to stimulate the growth of erythroid progenitors in vitro (5) . Inhibitory factors, most of which are leukocyte products, include lactoferrin (6) , prostaglandin E (7), acidic isoferritin (8) , and transferrin (9) . In most of the feedback systems described, the Ia (class II) surface antigenic system appears to play a role in the proliferative events in the marrow (10) (11) (12) . Both myeloid (colony-forming units granulocytic-monocytic [CFU-GM]) and erythroid progenitor cells (burst-forming units-erythroid and colony-forming units-erythroid [ BFU-E and CFU-Ej) express Ta antigenic determinants on their surfaces, although these progenitor cells appear to be generated from pluripotent stem cells lacking Ta antigens (13, 14) . Only Ia+ cells seem to be targets of these enhancing and inhibitory factors. It is also known that the in vitro growth of erythroid precursors can be enhanced by coculture with normal T cells (15) . The growth-enhancing effect of normal T cells, however, was shown to be the competitive outcome of at least two functionally distinct subpopulations: one that enhances burst formation, and one that limits it (15) . There is evidence that the inhibitory effect of the latter T cell subset on BFU-E growth may involve the Ia molecule, since this inhibitory action seems genetically restricted to cells that share expression of at least one HLA-DR (la) antigen (16) . Whether these effects are mediated by direct interactions of T cells with BFU-E or by indirect actions involving auxiliary cells or T cell factors remains to be determined.
The role of the Ia (class II) antigen system is certainly better characterized in immune responsiveness. Again, the phenomenon involves the balanced action ofregulator cells with opposite characteristics, i.e., helper and suppressor functions, both of which are known to be Ia-restricted at least in controlling the production of specific antibodies by B cells (17, 18) . Specific helper and suppressor factors produced by normal T cells or T cell hybridomas, many of which are restricted to specific recognition of antigen in conjunction with major histocompatibility complex (MHC) (class II) components (19) , also have been well documented, particularly in the mouse.
We were interested in determining whether a factor secreted by T lymphocytes would regulate not only the growth of bone marrow progenitor cells, but also the activity of T helper cells involved in immunoresponsiveness, by affecting the expression or recognition of the same cell surface molecules, i.e., the Ia antigens. For this purpose, we used a human factor, termed colony-inhibiting lymphokine (CIL), from the supernatant of a cloned T cell hybrid (designated MT 1) (20) . This protein factor has growth regulatory activity on bone marrow cells bearing Ia antigens (20) . As presented in this report, it also exerts a regulatory effect on the proliferation of Ia-positive lymphoblastoid cell lines. This positive correlation between Ia expression and CIL growth inhibition suggested that the factor might also be capable ofregulating immune responses. To test this hypothesis, we examined the effect of CIL in HLA-disparate mixed lymphocyte reactions (MLRs). CIL activity completely blocked these allo-responses by perturbing specific cell-to-cell interactions rather than eliciting a nonspecific cytotoxic effect. CIL activity did not appear to be restricted to any particular class II polymorphic determinant, nor did it appear to be species-specific, since the factor was also active in murine H-2 allogeneic MLR experiments. Finally, we present more direct evidence for the role ofthe Ia molecules as targets for factor-mediated regulation.
Methods
CIL production. MTI clone has been derived from one of the seven hypoxanthine-azaserine-resistant cell colonies detected 2 wk after fusion between the 6-thioguanine-resistant mutant (6TM) ofthe Jurkat human T-lymphoma cell line and phytohaemagglutinin-stimulated peripheral blood lymphocytes from a healthy female volunteer in the presence of polyethylene glycol 1500 (21) . MTl clone secretes in culture medium a factor (CIL) able to inhibit haematopoietic progenitor cell proliferation (20) . MTI clone cells were cultured in complete medium (RPMI 1640 medium containing 10% fetal calf serum [FCS] , 100 ,g streptomycin, 100 U penicillin, and 1 mM L-glutamine), and stocks of supernatant prepared using the same cell concentration (5 X 105/ml) and the same harvesting day (day 3 after last feeding) were used as the source of CIL factor. MTI cells cultured in synthetic medium (RPMI 1640, 100 Mg streptomycin, 100 U penicillin, 2 mM L-glutamine, 3 X 10-8 selenium dioxide, 0.015 M Hepes, pH 7.2, 5 Ag/ml insulin, 5 Mg/ml transferrin)
were also able to secrete the factor. Supernatant from 6TM T-lymphoma cells (20) originally used to construct the MT I hybrid cell and cultured under the same conditions as MT 1 was used as the control.
Human cell lines. The T cell lymphoma lines Jurkat and Molt 4, the promyelocytic leukemic cell line ML3, the Epstein-Barr virus (EBV)-transformed B cell lines WT18, WT20, WT46, WT50, WT51, WT52, and the Burkitt lymphomas, Daudi and Raji, were maintained in culture in complete medium in a 5% CO2 humidified incubator at 37°C. HLA typing of these cell lines has been described (21).
Human peripheral blood lymphocytes (PBL). PBL cells from normal donors were HLA-A, -B, and -C serotyped with highly selective reagents in the standard National Institutes of Health two-stage complementdependent lymphocytotoxicity technique at room temperature. HLA-DR determinants were typed on B cell-enriched suspensions using the same method adapted for B cells (21) .
Human MLR. Peripheral blood mononuclear cells from different HLA-typed donors were challenged in a MLR (22) made between groups of six wells containing MTI supernatant dilutions and those containing control supernatant dilutions. The cultures were harvested on the respective days of culture and evaluated as described above. Cell growth was also monitored by microscopic counting of the cells on alternate days after a Trypan blue dye-exclusion test. For this purpose the different cell lines were cultured in duplicate flasks and fed on alternate days by replacing twothirds of the cell suspension with normal medium containing either MTl or control supernatant. Where the effect of anti-DR monoclonal antibodies was studied (described below) on CIL-treated cell lines, a fixed quantity of antibodies (5 Mg/ 100 Ml of culture medium) and dilutions of the factor were added simultaneously.
Mice. Male CBA/J, (C57BI/6xCBA/J)Fl (B6CB), DBA/2, and female SJL mice were purchased from Jackson Laboratory (Bar Harbor, ME). B10.S(9R) mice were originally obtained from Dr. C. David (Mayo Clinic, Rochester, MN) and bred in our colony. All mice were used at 8-12 wk of age.
Murine cells. CBA thoracic duct lymphocytes (TDL) were used as responder cells both because of their high viability (>99%) and their reliably efficient responses. These cells were obtained from cannulated mice (23) Monoclonal antibodies. Mouse monoclonal antibodies directed against the common part (Sl.l9/9, B33. 1), or the allotypic site (MT2, E3. 15/4) of the HLA-DR molecule has been described previously (21, 24) . S1.34/28 is a monomorphic monoclonal antibody directed against the common part of the HLA-A, -B, and -C molecules (21, 25) . All of the monoclonal antibodies were affinity-purified on a Protein A column (26) and resuspended in phosphate-buffered saline (PBS) to a concentration of 2 mg/ml. Monoclonal antibodies B36. 1 (anti-T 1), B67. 1 (antiTl 1), and B33.1 (anti-DR) were from Dr. G. Trinchieri (The Wistar Institute ofAnatomy and Biology, Philadelphia, PA) (27) . Anti-T3 (antileu 4) was from Becton-Dickinson & Co., Mountainview, CA, and anti-T4 (OKT4) and anti-T8 (OKT8) were from Ortho Pharmaceuticals (Raritan, NJ). 1251 direct labeling of monoclonal antibodies was performed using the classical chloramine-T method with small modifications as published in reference 28.
Flow cytofluorometric analysis. Target cells (2-3 X 105) were treated with 20 Ml of the monoclonal antibodies at appropriate dilutions, incubated at room temperature for 30 min, and washed three times. The cells were then incubated in 20 Ml of fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse F(ab')2 antiserum (Cappel Laboratories, Cochranville, PA). Control cultures were treated with the Ig ofthe parental mouse myeloma (X 63), or with an irrelevant monoclonal antibody of the same isotype. In the experiment shown in Fig. 1 (29) . Approximately 106 cells/ml were placed in basic growth medium containing 0.5 gg/ml colcemid (Sigma Chemical Co., St. Louis, MO) for 45 min at 370C. The cells were then hypotonically treated for 30 min at 370C and fixed at room temperature with methanol and acetic acid (3:1). The cell suspension was then placed on a slide, Giemsa stained, and metaphase spreads were examined microscopically.
Rosetting tests. Ox erythrocytes (E) and ox erythrocytes sensitized with rabbit IgG anti-ox E (EA7S) (Cappel Laboratories) were used as the indicator system for the receptor for the Fc domain of IgG (FcR). E rosetting and EA7S (FcR)-rosetting assays were performed as described (30) . At least 300 cells were counted per sample.
Gelfiltration. Supernatant of MTI cells cultured in synthetic medium
was passed through a 0.9 X 55-cm Sephadex G-100 (Pharmacia Fine Chemicals, Piscataway, NJ) column at a flow rate of 2 ml/h, in the presence of 50 mg/liter of polyethylene glycol 6000 (BDH Chemicals, Poole, England) in PBS. Inhibitory activity was eluted in fractions corresponding to 85,000 mol wt. These fractions were pooled and tested at the appropriate reconstituted dilutions for inhibitory activity in a 6-d human MLR.
Results
Inhibitory effect ofCIL on the growth ofhuman cell lines. The supernatant from a human T cell hybrid clone (MT 1), the antigenic phenotype of which is given in Table I of culture in the presence of CIL. After a period of between 6 and 10 d, depending on the cell line, all of the CIL-sensitive cells in the cultures treated with the factor had died, whereas the controls grown in the presence of 10% control supernatant continued normal growth.
Effect ofCIL on ML3 cells treated with IFNy or IFNa. To test the hypothesis that DR-expression correlated with the inhibitory effect of CIL, we tested ML3 cells with the factor in the presence of IFNy (Table III) , which is known to enhance the quantitative expression of DR antigen on the cell surface. As expected, CIL treatment alone reduced ML3 cell growth in the first 2 d of culture, after which the cells grew well. This observation was confirmed by the stable percent inhibition calculated on days 4-6 (e.g., 52, 58, and 51% at 0.1% MTl supernatant dilution). Treatment with IFNy reduced the growth rate of the ML3 cells, but also enhanced CIL activity. The percent inhibition obtained in IFNy-treated ML3 cells vs. those not treated with IFN'y, upon addition ofMTI supernatant, differed significantly.
The difference was evident on days 4 and 5 ofcell culture, when the inhibition due to CIL alone ranged from 51 to 58% (at 0.1% MTl dilution), while that due to IFNy reached 96-97%. At a 0.01% MT1 dilution, the difference was even more striking, i.e., 38-31 vs. 87-97% of untreated and IFNy-treated cells, respectively. Note that percent inhibitions for the culture incubated with MT1 supernatant only were calculated using as 0% inhibition the [3H]TdR incorporation of untreated ML3 cells, whereas incorporation by cells treated only with IFNy was used as the 0% inhibition to calculate the inhibition of cultures treated with both IFNy and CIL. The reduction of cell growth due to IFN-y, per se, was also calculated, using the incorporation of untreated cells as 0% inhibition, and the percentage given in parentheses in Table III . To rule out the possibility that IFNy and CIL were acting synergistically independently of DR expression, we also tested ML3 cells that had been pretreated for 3 d with IFNy, washed three times, and then seeded in the presence of CIL only. Increased DR expression as a result of IFN'y treatment was verified by cytofluorometry using a FITCanti-DR monoclonal antibody (Fig. 1) The ML3 cell population varies in its DR' percentage depending on the day of harvesting and on the concentration of cell culture. These graphs were obtained by testing at different steps the cell population used for the experiment described in Table III. 43%, or 68 and 49% vs. 89 and 78% at the respective day and dilution tested). In parallel experiments under the same conditions, IFNa reduced ML3 growth rate (percent inhibition given in parentheses), but failed to enhance CIL activity significantly (Table III) . Inhibitory effect of CIL on human MHC-allogeneic MLR. To confirm that the inhibitory effect of CIL was dependent upon the presence of DR antigens or DR-associated structures on the target cell surface and to determine the role, if any, of CIL in regulating the immune response, we turned to experiments involving MHC-allogeneic MLRs. The effect ofCIL treatment on proliferative responses in various human MLR combinations is shown in Fig. 2 . The peak of the reaction was between days 5 and 7, depending on the combination of responder and stimulator. Negative controls were MLRs using irradiated stimulators and responders from the same donor. In parallel, the same combinations of cells used for the positive control were seeded in the presence of 10% MTI supernatant. The [3H]TdR incorporation of the responder cells treated with the factor was consistently lower than that of the negative control. Titration experiments showed that CIL dilutions as low as 0.15-0.01% were still able to block MLRs (Fig. 3) . In this respect, the CIL factor was apparently more effective for the A anti-C' and B anti-C' responses at lower dosages than for the C anti-A' or C anti-B' MLRs. The sensitivity, however, did not correlate with any polymorphic DR phenotype, as ascertained in titration experiments done using other donors (not shown). To determine whether the activity of CIL was directed primarily to the stimulator or the responder cell population in the mixed reaction, we pretreated responders and irradiated stimulators with the MT1 supernatant (10% final concentration) independently for 3 h at 4VC, washed them in cold buffer, and then seeded them for the assay. Results from three sets of MLRs (Fig. 4) ofthe semi-allogeneic anti-Fl culture, whereas the same response was markedly inhibited in the presence ofCIL. On all days tested, the level ofincorporation for the suppressed group did not exceed the background levels of controls stimulated with syngeneic irradiated CBA cells. Further studies with CIL in murine MLR cultures paralleled the findings in the human system (Figs. 3 and 4), i.e., supernatant used at a 0.01% dilution was still inhibitory, and preincubation of stimulators and not responders with the factor was sufficient to suppress the alloreactive response (not shown).
CBA responses in a 4-d MLR directed against a panel of irradiated stimulator spleen cells from strains expressing different H-2 haplotypes (e.g., H-2bdt4) were all significantly inhibited by the presence ofMT 1 supernatant in the cultures (Fig. 7) . This apparent non-Ia-restricted activity ofCIL paralleled the findings in human MLRs (Figs. 2-5 ). In addition, an assay to test the temporal requirements for CIL in culture indicated that its presence was critical at the early stages of the alloresponse (0-48 h), after which no inhibition could be induced (in the 4-d CBA MLR response) (Fig. 8) .
Effect ofanti-DR monoclonal antibody on human MLRs and on human cell lines treated with CIL. Further evidence that the DR molecule serves as a receptor for CIL, a notion suggested by the IFNs as well as by the MLR experiments, was obtained in analysis using mouse monoclonal anti-DR antibodies to prevent CIL activity. Whereas anti-DR antibodies could not be used to inhibit CIL activity in MLRs because they themselves block the reaction, they were successfully used to reduce CIL inhibition of growth activity directed against sensitive cell lines. The results in Table IV show that monomorphic anti-DR monoclonal antibodies parallel the action of CIL obtained by gel-filtration on MLRs in a 6-d kinetics experiment, while in Table V 
Discussion
The present results demonstrate that the expression of Ia-like molecules on the surface of the target cells is a requirement for the inhibitory activity of the human T cell-secreted factor CIL. This correlation between DR expression and CIL sensitivity was suggested in our previous studies (20) and seems to be the only feature CIL shows in common with other factors proven to be active in limiting the in vitro growth of Ia-positive bone marrow progenitor cells. The inhibitory pattern on myeloid progenitors, as well as the biochemical characteristics, are in fact unlike those shown by lactoferrin (85,000-100,000 mol wt), for example, which indirectly affects the growth of CFU-GM by inhibiting the production of CSF by monocytes (6) . This precludes experimental demonstrations of its effects on cultures maximally stimulated by an exogenous CSF, such as GCT-conditioned medium (31), which was the way CIL was originally tested (20) . Acidic isoferritin (450,000-500,000 mol wt), on the other hand, inhibits colony formation by direct action on CFU-GM, as does (Table  II and Fig. 3 Table II. itation of labeled CIL cross-linked to cell membrane receptors using anti-DR monoclonal antibodies. Exposure to the factor for 3 h at 40C was sufficient to block stimulator activity in MLRs even after washing. The partial inhibition seen on some independently treated responders (e.g., responder A in Fig. 4 ) might be due to absorption of the factor by the DR' cells present in the responder population and subsequent release during 6 d of the MLR.
Evidence that the DR molecule can be the receptor for CIL also came from the inhibition experiment on sensitive cell lines using mouse anti-DR monoclonal antibodies. The results showed that the factor did not block the binding ofanti-DR monocional antibodies to a DR' cell target, although these antibodies completely abrogated the factor activity on the same target cells (Tables V and VI). This can be explained by possible differences in affinity between factor and antibodies for the DR antigen, or differences in the quantity necessary to achieve the effect of the factor vs. the monoclonal antibodies. Since the inhibition cannot be proven to be reciprocal (i.e., antibody blocked by the factor as well as the factor blocked by antibody) even when limiting quantities of the antibody are used and the MTl supernatant concentration is increased to 50%, a third hypothesis must also be taken into consideration. CIL may act on its own receptor, independent of the DR molecule but interacting somehow with it at the cell surface. However, it is interesting to note that even ifthe same type ofinhibition is displayed by anti-DR monoclonal antibodies and by the factor in MLRs, suggesting that this DR molecule-mediated cell activity can be regulated by both agents, 106 mouse hybrid cells can secrete 50 ,g of antibody into their supernatant in 24 h, and that this supernatant is effective only ifdiluted no more than 1:1 (Table IV) . In comparison, 106 MTl cells secrete, in the same period oftime, sufficient CIL to render the supernatant effective at a 1:100,000 dilution on the same target.
Because the factor also acts on mouse target cells, a convenient in vivo system exists for investigations of the physiological significance of the factor in both hematopoiesis and generation ofthe immune response. The activity ofCIL on the bone marrow cells of normal mice, as well as the potential role of this factor in preventing graft-vs.-host reactions, are currently under investigation. These experiments should confirm, for instance, the etiology of severe aplastic anemia, hypothesized to be the outcome of an unbalanced activity due to a subpopulation of T lymphocytes that blocks the differentiation of the hemopoietic precursors via an inhibitory secreted factor (37, 38) . In the MLR experiments, as in the CFU-GM and BFU-E assays, it is the fraction corresponding to 85 kD ofthe gel filtered MTl SN that expresses inhibitory activity. The fact that both activities are contained in the same fraction allows us to postulate that it is actually the same factor that seems to act both on hematopoietic cell targets and on cells ofthe immune response. Purified material will provide a definite answer if CIL is really the link between the two systems using a common "receptor,"
the Ia-like molecule.
